OmniScience is thrilled to announce that accomplished SaaS engineering executive Colin Hendricks has joined the team as Chief Technology Officer (CTO). Colin’s extensive experience in scaling secure, compliant software solutions for regulated industries positions OmniScience for its next phase of growth - empowering clinical development teams with trustworthy, high-quality AI-driven insights from clinical trial data.
“OmniScience is the leading agentic AI team working in clinical research. Our team has worked on every kind of clinical trial data. Our team of expert PhD trained clinical data scientists have applied every AI technique, from analytical to generative. We have worked across datasets spanning 100s of clinical trials across many indications. Our team knows how to turn clinical trial data into knowledge - for diagnostics, clinical trial analytics, biomarkers, clinical decision support, biopharma market intelligence and more,” said Angela Holmes, Co-founder & CEO of OmniScience. “Colin’s addition to our team brings the critical skill of how to productize and scale our data scientists’ leading edge AI innovations across the clinical research industry.”
Hendricks brings a proven track record to OmniScience, leading technology organizations that have built scalable and compliant enterprise software to address complex business needs in regulated industries. Hendricks previously led engineering teams in the development of scalable, AI-driven products that manage massive datasets with real-time responsiveness for tens of thousands of customers. “I love building impactful new things with smart people. I’m grateful to have this opportunity to apply the amazing new capabilities of AI to the life sciences to help bring new treatments to market faster,” Hendricks said.
Hendrick’s impressive background provides deep expertise in building high-quality software systems - skills essential to OmniScience’s commitment to align with the highest standards of security, reliability, and scalability in clinical trials. “Colin’s expertise in leading agile software development teams to deliver compliant enterprise applications in regulated environments complements our team’s strong clinical data science and AI backgrounds.” said Sam Regenbogen, VP of GenAI at OmniScience. “I've personally worked on NLP-driven insights for biomedical teams for over a decade in collaborations between teams from Baylor College of Medicine, IBM Watson, and MD Anderson Cancer Center. Using the capabilities of today’s LLMs, OmniScience is able to accomplish what we only dreamed of a decade ago - generating real, actionable insights to advance research and get more treatments to patients. Colin’s leadership will enable us to scale our clinical trial agentic architecture to benefit users across the clinical research industry.”
Join us in welcoming Colin Hendricks to the team!
About OmniScience
OmniScience is the first and only company in the world to enable genAI as a personal data analyst for on-demand insights into unified clinical trial data at enterprise scale. Our team of clinical data science experts are applying analytical and generative AI to revolutionize the way biotech and pharma unifies clinical trial data to streamline clinical trials and reduce timelines. Founded in 2019 as a data science CRO, OmniScience has applied leading edge AI/ML across many clinical trials to support precision diagnostics, biomarker analytics, clinical trial analyses, clinical decision support, and market intelligence.
